We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Suspends 136 Drugs Due to Flawed Bioequivalence Studies
EMA Suspends 136 Drugs Due to Flawed Bioequivalence Studies
The European Medicines Agency is recommending halting sales of 136 drugs whose approval came from flawed studies performed at the Semler Research Centre in India.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor